Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131261 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
A Phase 2 study, sponsored by Valerio Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00131261: Completed Phase 2 study, sponsored by Valerio Therapeutics.
NCT00131261 is a Phase 2 study that has completed, run by Valerio Therapeutics. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131261, a Phase 2 study, has completed, sponsored by Valerio Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents, including dexamethasone, a well-established agent in relapsing myeloma.
Interventions
- DRUG Dexamethasone
- DRUG PXD101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00131261 record still lists
NCT00131261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00131261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00131261 about?
NCT00131261 is a clinical study titled "Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma". The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs...
What is the current status of trial NCT00131261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2005-01. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00131261?
The interventions under investigation include: Dexamethasone (DRUG), PXD101 (DRUG).
Who is sponsoring clinical trial NCT00131261?
This trial is sponsored by Valerio Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00131261's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia